Related Experiment Video
Updated: May 27, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches
1Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Despite international efforts, the treatment of recurrent glioblastoma (GBM) remains challenging. Although advances in surgical resection, the use of radiotherapy, and, predominantly, improved medical therapies have led to incremental improvements in median survival, few options exist for the management of recurrent or resistant disease. Insight into the molecular pathogenesis of GBM has led to the recent development of targeted therapeutic strategies aimed at the interruption of key molecular signaling pathways. However, due to the complex and redundant activation of the signaling mechanisms in GBM tumors, the evaluation of targeted agents in clinical trials has been largely limited. The ongoing effort to identify effective strategies for the treatment of recurrent GBM includes combination strategies with agents that target complementary or redundant pathways. Incorporation of novel trial designs that permit simultaneous evaluation of several agent combinations and allow for rapid discontinuation of ineffective regimens can accelerate the clinical evaluation of such candidate regimens. This review discusses strategies and outcomes of existing and emerging treatment approaches, and the challenges associated with the integration of novel therapies into clinical practice.
Insights
Treating recurrent glioblastoma (GBM) is difficult, with limited options for patients. New combination therapies and trial designs offer hope for more effective glioblastoma treatments.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Molecular Pathology
Background:
- Recurrent glioblastoma (GBM) presents significant treatment challenges despite advances in surgery, radiotherapy, and chemotherapy.
- Existing therapies offer incremental survival benefits, but effective management for recurrent or resistant disease remains limited.
- Understanding GBM's molecular complexity is crucial for developing targeted therapies.
Purpose of the Study:
- To review current and emerging treatment strategies for recurrent glioblastoma.
- To discuss the challenges in evaluating and integrating novel therapies into clinical practice.
- To highlight the potential of combination therapies and innovative clinical trial designs.
Main Methods:
- Review of existing literature on glioblastoma treatment.
- Analysis of targeted therapeutic strategies and their limitations.
- Discussion of novel clinical trial designs for evaluating combination therapies.
Main Results:
- Targeted therapies face challenges due to complex and redundant signaling pathways in GBM.
- Combination strategies targeting complementary pathways are a key focus for recurrent GBM.
- Novel trial designs can accelerate the evaluation of multiple agent combinations.
Conclusions:
- Effective treatment of recurrent glioblastoma requires innovative therapeutic strategies.
- Combination therapies and adaptive clinical trials are essential for advancing GBM treatment.
- Overcoming challenges in integrating new therapies is critical for improving patient outcomes.
